Leukocyte Patents (Class 424/93.71)
  • Patent number: 10688130
    Abstract: Methods and compositions are provided for treating a subject for aging-associated conditions, e.g., cognitive impairment conditions. Aspects of the methods include administering a young plasma-comprising blood product to an individual in need thereof, e.g., an individual suffering from or at risk of developing the aging-associated condition, e.g., aging-associated cognitive impairment. Also provided are compositions and kits thereof that find use in practicing methods of the invention.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: June 23, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, U.S. GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Anton Wyss-Coray, Saul A. Villeda, Joseph M. Castellano, Jinte Middeldorp, Martin S. Angst, Jian Luo
  • Patent number: 10669299
    Abstract: Labeled nucleotide analogs comprising at least one avidin protein, at least one dye-labeled compound, and at least one nucleotide compound are provided. The analogs are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The analogs are detectable with high sensitivity at desirable wavelengths. They contain structural components that modulate the interactions of the analogs with DNA polymerase, thus decreasing photodamage and improving the kinetic and other properties of the analogs in sequencing reactions. Also provided are nucleotide and dye-labeled compounds of the subject analogs, as well as intermediates useful in the preparation of the compounds and analogs. Compositions comprising the compounds, methods of synthesis of the intermediates, compounds, and analogs, and mutant DNA polymerases are also provided.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Lubomir Sebo, Honey Osuna, Stephen Yue, Yuri Lapin
  • Patent number: 10653722
    Abstract: Graft-versus-host disease (GVHD) is a lethal complication of allograft transplantation. The current strategy of using immunosuppressive agents to control GVHD may cause general immune suppression and limit the effectiveness of allograft transplantation. Adoptive transfer of regulatory T cells (Treg) can prevent GVHD in rodents, indicating the therapeutic potential of Treg for GVHD in humans. However, the clinical application of Treg-based therapy is hampered by the low frequency of human Treg and the lack of a reliable model to test their therapeutic effects in vivo. Human alloantigen-specific Treg are generated from antigenically-naïve precursors in a large scale ex vivo using allogeneic activated B cells as stimulators. Here, a human allogeneic GVHD model is established in humanized mice to mimic GVHD after allograft transplantation in humans.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: May 19, 2020
    Assignee: THE UNIVERSITY OF HONG KONG
    Inventors: Wenwei Tu, Yinping Liu, Jian Zheng
  • Patent number: 10621188
    Abstract: This disclosure is directed to a method for scoring and ranking candidate HLA-compatible unrelated hematopoietic cell donors (URD) for patients with AML or myelodysplastic syndrome. Candidate donors are scored based on KIR/HLA allele and genotype combinations. The method disclosed herein permits ranking and selection of advantageous donors that predict improved clinical outcomes of hematopoietic stem cell transplantation.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 14, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventor: Katharine Hsu
  • Patent number: 10596242
    Abstract: The present description relates to T-cell receptors (TCRs) binding to tumor-associated antigens (TAAs) for targeting cancer cells, T-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to TCRs and their variants that bind to HLA class I or II molecules with a peptide, such as IGF2BP3-001 have the amino acid sequence of KIQEILTQV (SEQ ID NO:1). The present description further relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: March 24, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Dominik Maurer, Leonie Alten, Sebastian Bunk
  • Patent number: 10590385
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 17, 2020
    Assignee: NKMAX CO., LTD.
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • Patent number: 10556053
    Abstract: A system for collecting MNCs to be treated with irradiation comprises a fluid circuit comprising a product container for receiving a MNC product. The system comprises a separator to work in association with the fluid circuit, the separator comprising a chamber for separation into RBCs, plasma, and an interface carrying MNCs between the RBCs and the plasma. A microprocessor-based controller is in communication with the separator, wherein the controller receives input of a target hematocrit for the MNC product. The controller also receives input for a total volume of whole blood and a number of cycles, and directs the interface and a portion of the RBCs into the product container for a resulting product volume comprising a volume of MNCs and a volume of RBCs. The controller automatically adjusts a RBC volume so that a ratio of RBCs within the MNC product to MNC product equals the target hematocrit.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: February 11, 2020
    Assignee: Fenwal, Inc.
    Inventors: Tanima Jahan Abedin, Katherine N. Radwanski
  • Patent number: 10533157
    Abstract: Cancer immunotherapy using genetically engineered NK cells is enhanced by expression of recombinant co-stimulatory molecules to deliver co-stimulatory signals to a recipient host's immune cells to enhance an immune response.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: January 14, 2020
    Assignees: NANTBIO, INC., NANT HOLDINGS IP, LLC
    Inventors: Patrick Soon-Shiong, Kayvan Niazi, Shahrooz Rabizadeh
  • Patent number: 10494603
    Abstract: The present invention relates to a medium composition containing an Ecklonia cava extract for dedifferentiation into an induced pluripotent stem cell. Also, the present invention relates to a method for differentiating an induced pluripotent stem cell produced by using the medium composition into adipocytes.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: December 3, 2019
    Assignee: BBHC Co., LTD.
    Inventors: Sang Yeon Lee, Won Ju Jung, Ho Bin Kim, Min Sun Oh, Kye Ho Lee
  • Patent number: 10435456
    Abstract: The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces. In particular embodiments, the present invention provides nucleic acids and amino acid sequences useful for improving/increasing protein expression on the cell surface. In several embodiments, the sequences are operably linked to the N-terminal end of the protein of interest. The nucleic acid sequence encoding the sequence tag and the protein can comprise part of an expression vector. The protein can be expressed with the N-terminal sequence tag. In certain embodiments, the sequences of the present invention can be used with one or more chaperone or accessory proteins. In particular embodiments, the one or more chaperone/accessory proteins are encoded by the same vector or separate vectors.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: October 8, 2019
    Assignee: The Johns Hopkins University
    Inventors: Jennifer Pluznick, Blythe Shepard, Niranjana Natarajan
  • Patent number: 10428142
    Abstract: The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: October 1, 2019
    Assignee: bluebird bio, Inc.
    Inventors: Jordan Jarjour, Alexander Astrakhan, Michael Certo
  • Patent number: 10369141
    Abstract: Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: August 6, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Nipavan Chiamvimonvat, Bruce D. Hammock
  • Patent number: 10351824
    Abstract: The present disclosure relates to a novel process for expanding T cells, such as autologous T cells, cell populations therefrom, pharmaceutical compositions comprising the said cell populations and use of the cells and compositions for treatment, particular the treatment or prophylaxis of virus infection and/or cancer, for example in immune compromised or immune competent human patients.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: July 16, 2019
    Assignees: Cell Medica Limited, Baylor College of Medicine
    Inventors: Cliona M. Rooney, Ann M. Leen, Juan F. Vera, Minhtran V. Ngo, Rainer Ludwig Knaus
  • Patent number: 10266805
    Abstract: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1a?CD5? or CD34+CD7+CD1a?CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: April 23, 2019
    Assignee: Sunnybrook Health Sciences Centre
    Inventors: Juan Carlos Zuniga-Pflucker, Geneve Awong, Ross La Motte-Mohs
  • Patent number: 10195231
    Abstract: Modified natural killer cells, pharmaceutical compositions comprising the modified natural killer cells and at least one pharmaceutically acceptable carrier or excipient, uses of the modified natural killer cells, and methods for identifying depleted natural killer cells and culturing the modified natural killer cells are provided.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: February 5, 2019
    Assignee: Academia Sinica
    Inventors: Nan-Shih Liao, Jan-Mou Lee
  • Patent number: 10172885
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: January 8, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Martin Pulé, Khai Kong, Shaun Cordoba
  • Patent number: 10166257
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 1, 2019
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10130659
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 20, 2018
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10059743
    Abstract: The present invention relates to a peptide derivative for regulating the thymic stromal lymphoid protein-mediated signaling and a pharmaceutical composition including the peptide derivative for preventing and treating allergy and asthma diseases and, more particularly, to a peptide derivative represented by Chemical Formula 1 and a pharmaceutical composition including the peptide derivative for preventing and treating allergy and asthma diseases. According to the present invention, provided are a peptide derivative capable of effectively inhibiting the formation of an inflammatory response of allergy and asthma diseases and a pharmaceutical composition including the peptide derivative. By using the present invention, various allergy and asthma diseases can be fundamentally prevented or treated.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: August 28, 2018
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS
    Inventors: Youngjoo Byun, Ki Yong Lee, Kiho Lee, Young Ho Jeon, Yong Woo Jung
  • Patent number: 9993502
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 12, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Patent number: 9975959
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: May 22, 2018
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Nicholas Marshall, John Blazeck, Wei-Cheng Lu
  • Patent number: 9969975
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: May 15, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Patent number: 9957291
    Abstract: Protected fluorescent reagent compounds and their methods of synthesis are provided. The compounds are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The compounds contain fluorescent dye elements, that allow the compounds to be detected with high sensitivity at desirable wavelengths, binding elements, that allow the compounds to be recognized specifically by target biomolecules, and protective shield elements, that decrease undesirable contacts between the fluorescent dye elements and the bound target biomolecules and that therefore decrease photodamage of the bound target biomolecules by the fluorescent dye elements.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: May 1, 2018
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Lubomir Sebo, Jeremiah Hanes, Gene Shen, Louis Brogley, Stephen Yue, Frank Zheng, Yuri Lapin, John Lyle, Honey Osuna, Andrei Fedorov
  • Patent number: 9950011
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Patent number: 9950010
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Patent number: 9889160
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 13, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • Patent number: 9889161
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 13, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • Patent number: 9844569
    Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: December 19, 2017
    Assignee: The United State of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Patent number: 9809797
    Abstract: A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+ T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+ T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: November 7, 2017
    Assignee: NATIONAL INSTITUTES OF HEALTH (NIH) U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY
    Inventors: Cassian Yee, Yongqing Li
  • Patent number: 9808505
    Abstract: The influence of TF, endothelial cell protein C receptor (EPCR) and protease activated receptor-1 (PAR1) on tumor growth of malignant pleural mesothelioma (MPM) is disclosed. MPM cells that lack or express TF, EPCR or PAR1 and a murine orthotopic model of MPM led to the discovery that intrapleural administration into nude mice of REN MPM cells expressing TF and PAR1 but lacking EPCR and PAR2 generated large pleural cavity tumors. Suppression of TF or PAR1 expression markedly reduced tumor growth. Overexpression of TF in non-aggressive MPM cells expressing EPCR and PAR1 but exhibiting minimal levels of TF failed to alter their tumorigenicity. Introduction of EPCR expression in aggressive MPM cells attenuated tumor growth whereas EPCR silencing in non-aggressive MPM cells overexpressing TF increased tumorigenicity of non-aggressive cells. Expression of EPCR by MPM cells suppresses tumor growth and treats MPM.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 7, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Usha R. Pendurthi, Vijaya M. R. Lella, Shivakeshava Gaddam, Steven Idell
  • Patent number: 9763983
    Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 19, 2017
    Assignee: ANTHROGENESIS CORPORATION
    Inventors: Xiaokui Zhang, Robert J. Hariri, Vanessa Voskinarian-Berse, Lin Kang, Eric Law, Stewart Abbot
  • Patent number: 9745552
    Abstract: The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: August 29, 2017
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Stephan Fricke, Frank Emmrich, Nadja Hilger
  • Patent number: 9597356
    Abstract: The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is IL-15. Meanwhile a pharmaceutical composition comprises the above dendritic killer cell population for treating cancers is also disclosed in the present invention.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: March 21, 2017
    Assignee: FULLHOPE BIOMEDICAL CO., LTD
    Inventor: Jan Mou Lee
  • Patent number: 9504717
    Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: November 29, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel Strober, Robert Lowsky
  • Patent number: 9422351
    Abstract: The present invention relates to B7-H4-specific chimeric antigen receptor compositions and methods of use thereof.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: August 23, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • Patent number: 9404083
    Abstract: A technique is needed which can amplify NK cells in vitro and prepare optimum number of NK cells for the adoptive immunotherapy. A method for amplifying NK cells is provided which comprises steps of: preparing cell population which is comprised of NK cells, removing T cells from the cell population which is comprised of NK cells, and, after removal of T cells, cultivating the remaining cells in a medium supplemented with 2500 to 2831 IU/mL of IL-2. The method for amplifying NK cells of the present invention may comprise a step of removing hematopoietic progenitor cells from the cell population. The present invention provides a pharmaceutical composition for adoptive immunotherapy, comprising NK cells which are prepared by the amplifying method of the present invention.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: August 2, 2016
    Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, TELLA, INC.
    Inventors: Yoshikazu Yonemitsu, Yui Harada, Satoru Saito, Yuichiro Yazaki, Masato Okamoto, Takefumi Ishidao
  • Patent number: 9394517
    Abstract: The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 19, 2016
    Assignee: IMCYSE SA
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 9376482
    Abstract: The present invention relates to a method for producing a cell line expressing a stabilized functional single chain-antigen-recognizing genetic construct (scARC), comprising a genetic construct of the human scARC to be expressed, comprising the domains huV1/2—Li-huV2/1—C4/3 and a genetic construct comprising the corresponding hetero-/(homo-)dimeric domain C3/4, containing xenogenic, in its special case murine amino acid exchanges in the domains C4/3 and C3/4, wherein co-expression of the genetic constructs of the scARC-fragments occurs through the cell. Preferably, the scARCs are single chain-TCRs (scTCRs) or antibody-scFv-fragments, which further preferably recognize tumor associated peptide antigens (TAA). The present invention further relates to a gp100-protein-specific T-cell response mediated ?/? T-cell receptor rationally mutated by means of the method of the present invention and its uses.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: June 28, 2016
    Assignee: Johannes Gutenberg-Universität Mainz
    Inventors: Ralf-Holger Voss, Matthias Theobald, Ratna Sari Intan Pöndl, Renate Engel, Simone Thomas
  • Patent number: 9376663
    Abstract: The present invention is directed to in vitro methods for promoting expression of G-protein coupled receptor 15 (GPR15) on T cells, GPR15+ enriched populations of T cells generated using these methods and compositions thereof, as well as methods of using these T cell populations for therapeutic purposes.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: June 28, 2016
    Assignee: New York University
    Inventors: Dan R. Littman, Sang-Won Kim
  • Patent number: 9328171
    Abstract: [Problem] To provide an anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. [Means for Solution] An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model, and then the present invention was completed.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 3, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Hiromu Sato, Daisuke Yamajuku, Kazunori Arai, Mako Ogino
  • Patent number: 9290736
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: March 22, 2016
    Assignee: Case Western Reserve University
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • Patent number: 9289452
    Abstract: Embodiments of the present invention provides bone graft compositions, and methods for their use and manufacture. A bone graft composition may include a first amount of non-demineralized cancellous bone. The composition may further include a second amount of demineralized cancellous bone. The composition may also include a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: March 22, 2016
    Assignee: AlloSource
    Inventor: Yaling Shi
  • Patent number: 9265795
    Abstract: The present invention provides a therapeutic composition comprising: (i) Trolox, Na+, K+, Ca2+, Mg2+, Cl?, H2PO4?, HEPES, lactobionate, sucrose, mannitol, glucose, dextran-40, adenosine, glutathione; and (ii) stem cells or progenitor cells, wherein the composition does not comprise a dipolar aprotic solvent, in particular DMSO. The present invention also relates to methods of formulating said composition for cryopreservation and subsequent direct administration to a patient, and medicaments comprising said composition.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: February 23, 2016
    Assignee: RENEURON LIMITED
    Inventors: Andrew Hope, Erik Miljan, John Sinden
  • Patent number: 9265822
    Abstract: The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infaction also are described.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: February 23, 2016
    Assignee: Saint Louis University
    Inventor: Daniel Hoft
  • Patent number: 9260696
    Abstract: A method for producing NK cells from pluripotent stem cells, which includes culturing pluripotent stem cells in a first serum-free medium, aggregating the undifferentiated stem cells to form embryoid bodies, which are cultured to produce hematopoietic precursor cells, and culturing the precursor cells in a serum-free medium to produce the NK cells. Methods for using such NK cells, e.g., in the treatment of cancer and infectious disease are also provided.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: February 16, 2016
    Inventors: Dan S. Kaufman, David A. Knorr
  • Publication number: 20150147304
    Abstract: The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PI3K inhibitors, PI3K inhibitors for particular uses, and kits.
    Type: Application
    Filed: October 29, 2014
    Publication date: May 28, 2015
    Inventor: Matthias Michael Merkenschlager
  • Publication number: 20150139971
    Abstract: An object of the present invention is to establish a method that enables safe and convenient large-scale preparation of regulatory dendritic cells. The present invention provides a method for preparing regulatory dendritic cells, which comprises culturing cells that can be induced to result in regulatory dendritic cells in the presence of a [1,2,4]triazolo[1,5-a]pyrimidine derivative.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Applicants: NIPPON KAYAKU KABUSHIKI KAISHA, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Satoru TODO, Kenichiro YAMASHITA, Susumu SHIBASAKI
  • Publication number: 20150139943
    Abstract: Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8?); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1BB); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) (e.g., a cytoplasmic signaling domain of CD3?). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.
    Type: Application
    Filed: October 17, 2014
    Publication date: May 21, 2015
    Applicants: National University of Singapore, St. Jude Children's Research Hospital
    Inventors: Dario Campana, Ko Kudo
  • Publication number: 20150139904
    Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 21, 2015
    Applicant: University of Miami
    Inventors: Omaida Velazquez, Sylvia Daunert, Pirouz Daftarian, Liu Zhao-Jun, Sapna Deo
  • Publication number: 20150139946
    Abstract: Provided is a method for monitoring a gene mutation associated with a cancer in a patient over time. Also provided is a method of selecting and/or applying treatment or therapy for a subject.
    Type: Application
    Filed: October 19, 2014
    Publication date: May 21, 2015
    Inventors: Mark G. Erlander, Karena Kosco, Cecile Rose Vibat